EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy

Eyepoint Pharma ((EYPT)) announced an update on their ongoing clinical study.

EyePoint Pharmaceuticals has recently completed a Phase 2 clinical study titled A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR). The study aimed to evaluate the efficacy and safety of EYP-1901, a novel intravitreal drug, in improving the condition of patients with NPDR. This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness.

The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, administered as a single intravitreal injection designed to release vorolanib over 6 to 9 months. The study compared two doses of EYP-1901 against a sham injection to assess its effectiveness.

The study was interventional, with a randomized allocation and a parallel intervention model. It was triple-masked, meaning the participant, care provider, and investigator were unaware of the group assignments. The primary purpose was treatment-focused.

The study began on September 28, 2022, and was completed with results submitted on July 9, 2025. The last update was recorded on August 13, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for investors to track the development and potential market release of EYP-1901.

This update could positively influence EyePoint Pharmaceuticals’ stock performance and investor sentiment, given the potential of EYP-1901 to address a significant unmet medical need. The results could also impact the competitive landscape in the diabetic retinopathy treatment market, where other companies are also vying for innovative solutions.

The study is completed, and further details are available on the ClinicalTrials portal.